The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations to treat adults with relapsed or refractory ...

GSK plc announced the approval of Blenrep combinations by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma. The approval ...

A Japan expansion cohort is set to further evaluate the DREAMM-8 protocol in Japanese patients. Results for Japanese participants will be presented at a future scientific meeting. About Blenrep ...

A Japan expansion cohort is set to further evaluate the DREAMM-8 protocol in Japanese patients. Results for Japanese participants will be presented at a future scientific meeting. Blenrep is an ...

GSK said combinations of its blood-cancer treatment, Blenrep, have been approved by Japan's Ministry of Health, and that it expects more approvals through the year. The U.K. pharma company said ...

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma. The London-based ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

Japan approves GSK’s Blenrep combinations for multiple myeloma treatment ...

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...